Merck Pulls Plug On Two Keytruda Late-Stage Studies On Underwhelming Data

Thursday, Merck & Co Inc (NYSE:MRK) provided updates on two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630. Merck is discontinuing the Phase 3 KEYNOTE-867 trial evaluating Keytruda (pembrolizumab) in combination with stereotactic body radiotherapy (SBRT) for stage I or II non-small cell lung cancer, including those who are medically inoperable or have refused surgery. The decision is based on the recommendation of an independent Data Monitoring Committee (DMC), which reviewed data from a planned interim analysis. Also Read: Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss ...